News

'Game-Changer': Seattle Doc's Research Is Saving Kids Like Katie With Rare Cancer

'Game-Changer': Seattle Doc's Research Is Saving Kids Like Katie With Rare Cancer

A Children’s Oncology Group trial led by Seattle Children’s Dr. Julie Park finds that two stem-cell transplants, not just one, improve outcomes for young children with high-risk neuroblastoma, and has become the new standard of care across North America. Katie Belle was diagnosed at 3-years-old with high-risk neuroblastoma. Her chances of survival were just 35 percent. Almost six years after participating in the trial at Seattle Children’s, Katie is an active third-grader with no signs of the disease.

About Seattle Children’s

Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation’s top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children’s bold initiative – It Starts With Yes: The Campaign for Seattle Children’s – to transform children’s health for generations to come.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.